ClinicalTrials.gg
CompletedNCT02748213Updated Nov 22, 2016Results posted

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

A Phase 2 interventional study of Xeloda and Taxotere in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 51 sites in 15 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-22.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
58th of 248
225 · median 68
Started
2002
with 19 others
Phase 2
157 of 264
11 open now
Registered
225th of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 58th largest by enrollment of the 248 interventional ones that give a count, is one of 20 that started in 2002, is one of 157 in phase 2, and was the 225th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of intravenous (IV) trastuzumab (Herceptin) and IV docetaxel (Taxotere), with or without oral capecitabine (Xeloda), in women with previously untreated HER2-positive advanced and/or metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, -positive advanced and/or breast cancer not amenable to curative therapy
  • At least one according to
  • (ECOG) performance status of 0 or 1
  • Baseline (LVEF) at least 50%

Exclusion criteria

Exclusion Criteria:

  • Pregnant, lactating, or women of who are not surgically sterile or not willing to use adequate methods
  • Previous treatment with Herceptin or other anti-HER therapies, or any previous chemotherapy for advanced or disease
  • Past medical history significant for any cardiac or central nervous system (CNS) disorders
  • Poor hematologic, renal, or hepatic function
  • Chronic therapy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Herceptin + Taxotere

    Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.

    Drug: Taxotere · Drug: Herceptin

  • Experimental
    Herceptin + Taxotere + Xeloda

    Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.

    Drug: Xeloda · Drug: Taxotere · Drug: Herceptin

Interventions

  • DrugXeloda

    Participants will receive oral Xeloda, 950 mg/m\^2 twice a day on Days 1 to 14 of each 21-day cycle.

    Also known as: capecitabine

  • Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.

    Also known as: docetaxel

  • Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.

    Also known as: trastuzumab

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)

    Tumor response was assessed by RECIST during the study. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. The percentage of participants with a best overall response for CR or PR was reported. The exact 95% confidence interval (CI) for one-sample binomial was determined using the Pearson-Clopper method.

    Time frame: Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)

Secondary outcomes

  1. Percentage of Participants With Death or Disease Progression According to RECIST

    Tumor response was assessed by RECIST during the study. Disease progression or progressive disease (PD) was defined as ≥20% increase in sum LD in reference to the smallest on-treatment sum LD, or the appearance of new lesions. The percentage of participants who died or experienced PD was reported.

    Time frame: Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)

  2. Progression-Free Survival (PFS) According to RECIST

    Tumor response was assessed by RECIST during the study. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-treatment sum LD, or the appearance of new lesions. PFS was defined as the time from start of treatment to the first event of death or PD. Participants without event at the time of analysis were censored at the latest date of last tumor assessment or last date in drug log. The median duration of PFS and corresponding 95% CI were estimated by Kaplan-Meier analysis and expressed in months.

    Time frame: Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)

  3. Percentage of Participants Who Died

    The percentage of participants who died from any cause was reported.

    Time frame: Continuously during treatment (up to 66 months) and at any time after treatment discontinuation until 18 months after last participant enrolled (up to 66 months overall)

  4. Overall Survival (OS)

    OS was defined as the time from start of treatment to date of death for any reason. Participants who were alive at the time of analysis were censored at the latest date of last tumor assessment, last drug intake, or last follow-up information. The median duration of OS and corresponding 95% CI were estimated by Kaplan-Meier analysis and expressed in months.

    Time frame: Continuously during treatment (up to 66 months) and at any time after treatment discontinuation until 18 months after last participant enrolled (up to 66 months overall)

  5. Duration of Response (DOR) According to RECIST

    Tumor response was assessed by RECIST during the study. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. PR was defined as ≥30% decrease in sum LD of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. DOR was defined as the time from first assessment of CR or PR until the first occurrence of documented PD, death, or withdrawal. The median DOR was reported and expressed in months.

    Time frame: Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)

07

Results

Posted Nov 22, 2016

Participant flow

Participant flow — Overall Study
MilestoneHerceptin + Taxotere + XelodaHerceptin + Taxotere
Started113112
Treated112110
Completed00
Not completed113112
Withdrew: Withdrawal prior to treatment12
Withdrew: Abnormal laboratory test10
Withdrew: Adverse event or intercurrent illness511
Withdrew: Death53
Withdrew: Insufficient therapeutic response5657
Withdrew: Violation of selection criteria20
Withdrew: Protocol violation64
Withdrew: Refused treatment*66
Withdrew: Failure to return10
Withdrew: Other3029

Outcome measures

PrimaryPercentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)

Tumor response was assessed by RECIST during the study. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. The percentage of participants with a best overall response for CR or PR was reported. The exact 95% confidence interval (CI) for one-sample binomial was determined using the Pearson-Clopper method.

Time frame:
Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)
percentage of participantsHerceptin + Taxotere + XelodaHerceptin + Taxotere
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)70.5 (61.18 to 78.77)72.7 (63.41 to 80.78)
Statistical analysis
  • Herceptin + Taxotere + Xeloda vs Herceptin + Taxotere · Chi-squared · p = 0.717 · Difference in response rates: 2.2 · 95% CI -10.17 to 14.56The approximate 95% CI for the difference in response (CR or PR) rates was determined using the Hauck-Anderson correction.
SecondaryPercentage of Participants With Death or Disease Progression According to RECIST

Tumor response was assessed by RECIST during the study. Disease progression or progressive disease (PD) was defined as ≥20% increase in sum LD in reference to the smallest on-treatment sum LD, or the appearance of new lesions. The percentage of participants who died or experienced PD was reported.

Time frame:
Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Death or Disease Progression According to RECIST
percentage of participantsHerceptin + Taxotere + XelodaHerceptin + Taxotere
Percentage of Participants With Death or Disease Progression According to RECIST67.977.3
SecondaryProgression-Free Survival (PFS) According to RECIST

Tumor response was assessed by RECIST during the study. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-treatment sum LD, or the appearance of new lesions. PFS was defined as the time from start of treatment to the first event of death or PD. Participants without event at the time of analysis were censored at the latest date of last tumor assessment or last date in drug log. The median duration of PFS and corresponding 95% CI were estimated by Kaplan-Meier analysis and expressed in months.

Time frame:
Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)
Reported as:
Median · months
Progression-Free Survival (PFS) According to RECIST
monthsHerceptin + Taxotere + XelodaHerceptin + Taxotere
Progression-Free Survival (PFS) According to RECIST17.9 (14 to 21)12.8 (10 to 16)
Statistical analysis
  • Herceptin + Taxotere + Xeloda vs Herceptin + Taxotere · Log Rank · p = 0.0449 · Hazard ratio (hr): 0.73 · 95% CI 0.53 to 0.99Hazard Ratio (HR) calculated using Herceptin + Taxotere arm as reference.
SecondaryPercentage of Participants Who Died

The percentage of participants who died from any cause was reported.

Time frame:
Continuously during treatment (up to 66 months) and at any time after treatment discontinuation until 18 months after last participant enrolled (up to 66 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsHerceptin + Taxotere + XelodaHerceptin + Taxotere
Percentage of Participants Who Died35.741.8
SecondaryOverall Survival (OS)

OS was defined as the time from start of treatment to date of death for any reason. Participants who were alive at the time of analysis were censored at the latest date of last tumor assessment, last drug intake, or last follow-up information. The median duration of OS and corresponding 95% CI were estimated by Kaplan-Meier analysis and expressed in months.

Time frame:
Continuously during treatment (up to 66 months) and at any time after treatment discontinuation until 18 months after last participant enrolled (up to 66 months overall)
Reported as:
Median · months
Overall Survival (OS)
monthsHerceptin + Taxotere + XelodaHerceptin + Taxotere
Overall Survival (OS)43.5 (40 to 50)47.3 (32 to NA)
Statistical analysis
  • Herceptin + Taxotere + Xeloda vs Herceptin + Taxotere · Log Rank · p = 0.4758 · Hazard ratio (hr): 0.85 · 95% CI 0.56 to 1.32HR calculated using Herceptin + Taxotere arm as reference.
SecondaryDuration of Response (DOR) According to RECIST

Tumor response was assessed by RECIST during the study. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels. PR was defined as ≥30% decrease in sum LD of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. DOR was defined as the time from first assessment of CR or PR until the first occurrence of documented PD, death, or withdrawal. The median DOR was reported and expressed in months.

Time frame:
Tumor assessments at Baseline, then every 6 weeks until Cycle 8 (cycle length of 21 days), then every 12 weeks until progressive disease and/or one year after enrollment; thereafter according to routine clinical practice (up to 66 months overall)
Reported as:
Median · months
Duration of Response (DOR) According to RECIST
monthsHerceptin + Taxotere + XelodaHerceptin + Taxotere
Duration of Response (DOR) According to RECIST15.9 (2.4 to 64.7)13.4 (2.1 to 55.1)

Adverse events

Collected over Continuously during treatment (up to 66 months) and up to 28 days after last dose (up to 66 months overall). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Herceptin + Taxotere + Xeloda—52/112 (46.4%)112/112 (100%)
Herceptin + Taxotere—51/110 (46.4%)107/110 (97.3%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventHerceptin + Taxotere + XelodaHerceptin + Taxotere
Febrile neutropeniaBlood and lymphatic system disorders16/11226/110
NeutropeniaBlood and lymphatic system disorders7/1127/110
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/1120/110
Neutropenic sepsisInfections and infestations5/1121/110
DiarrhoeaGastrointestinal disorders5/1120/110
PyrexiaGeneral disorders3/1124/110
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1123/110
Ejection fraction decreasedInvestigations0/1123/110
BronchopneumoniaInfections and infestations3/1120/110
VomitingGastrointestinal disorders3/1121/110
Most frequent other events
Showing 10 of 75
Most frequent other events
EventHerceptin + Taxotere + XelodaHerceptin + Taxotere
AlopeciaSkin and subcutaneous tissue disorders76/11268/110
DiarrhoeaGastrointestinal disorders75/11255/110
NauseaGastrointestinal disorders61/11239/110
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders57/1127/110
Oedema peripheralGeneral disorders28/11242/110
MyalgiaMusculoskeletal and connective tissue disorders15/11238/110
VomitingGastrointestinal disorders37/11230/110
AstheniaGeneral disorders35/11235/110
FatigueGeneral disorders35/11229/110
NeutropeniaBlood and lymphatic system disorders35/11223/110

Baseline characteristics

Full Analysis Set (FAS) Population: All participants, according to randomization scheme, who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Herceptin + Taxotere + XelodaHerceptin + TaxotereTotal
Mean52.7 ± 11.1851.6 ± 10.7452.1 ± 10.95
Sex: Female, Male
Sex: Female, Male(Participants)Herceptin + Taxotere + XelodaHerceptin + TaxotereTotal
Female112110222
Male000
08

Study locations

51 sites
  • Adelaide, 5011, Australia
  • Brisbane, 4066, Australia
  • Camperdown, 2050, Australia
  • Geelong, 3220, Australia
  • Melbourne, 3002, Australia
  • Melbourne, 3181, Australia
  • Perth, 6000, Australia
  • Southport, 4215, Australia
  • Porto Alegre, 91350-200, Brazil
  • Rio de Janeiro, 20560-120, Brazil
  • Sao Paulo, 01401-901, Brazil
  • Calgary, Alberta T2N 4N2, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Quebec, G1S 4L8, Canada
  • San Jose, 10103, Costa Rica
  • Turku, 20520, Finland
  • Besancon, 25030, France
  • Grenoble, 38000, France
  • Marseille, 13273, France
  • Paris, 75231, France
  • Pierre Benite, 69310, France
  • Rennes, 35042, France
  • Athens, 11526, Greece
  • Heraklion, 71110, Greece
  • Patras, 26500, Greece
  • Guatemala City, 01010, Guatemala
  • Legnago, 37045, Italy
  • Noale, 30033, Italy
  • Rozzano, 20089, Italy
  • Trento, 38100, Italy
  • Treviglio, 24047, Italy
  • Distrito Federal, 14080, Mexico
  • Merida, 97500, Mexico
  • Monterrey, 64020, Mexico
  • Monterrey, 64060, Mexico
  • Panama City, 0, Panama
  • Gdansk, 80-214, Poland
  • Szczecin, 71-730, Poland
  • Barcelona, 08035, Spain
  • Lerida, 25198, Spain
  • Sabadell, Barcelona, 08208, Spain
  • Zaragoza, 50009, Spain
  • Karlstad, 65185, Sweden
  • Västerås, 72189, Sweden
  • Ipswich, IP4 5PD, United Kingdom
  • Leeds, LS9 7TF, United Kingdom
  • Manchester, M20 4BX, United Kingdom
  • Northwood, HA6 2RN, United Kingdom
  • Oxford, OX3 7LJ, United Kingdom
  • Southampton, SO16 6YD, United Kingdom
  • Weston Super Mare, BS23 4TQ, United Kingdom
09

References and documents

Publications

  • Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2. PubMed 34037241 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Mar 2006 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 10 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2016
First posted
Apr 22, 2016
Start
Feb 2002
Primary completionActual
Mar 2006
CompletionActual
Jan 2008
Results first posted
Nov 22, 2016
Last update
Nov 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02748213
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 22, 2016
Start date
Feb 2002
Primary completion
Mar 2006
Completion
Jan 2008
Results posted
Nov 22, 2016
Last update
Nov 22, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Trastuzumab

Start the discussion